Shattuck Labs Inc at JPMorgan Healthcare Conference Transcript
Good morning. Welcome to the last day of the 41st JPMorgan Healthcare Conference. Hope you have all enjoyed the conference. My name is [Tim Jang]. I'm from the JPMorgan Healthcare Investment Banking team. It is my great pleasure to introduce this session speaker, Taylor Schreiber, CEO of Shattuck Labs. Without further ado, I'll pass it over to Taylor.
Thank you, [Ting]. Good morning. It's my pleasure to be here to present Shattuck to you, and thank you to the organizers of JPMorgan for the invitation to present the 2023 Healthcare Conference. Okay, there we go. These are my forward-looking statements. So Shattuck is a clinical-stage cancer immunotherapy company. We have 2 compounds, both from the ARC platform that are in a variety of Phase I clinical trials right now, and I'll tell you about where we are and what to expect this year from those trials today. We have a second platform, which is in the preclinical stage of development that is a series of gamma delta T cell
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
